NCT02421367View on ClinicalTrials.gov

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

March 31, 2018

Conditions
Dengue
Interventions
BIOLOGICAL

TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.

Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)

Trial Locations (2)

21201

University of Maryland, Center for Vaccine Development,, Baltimore

20910-7500

WRAIR, Clinical Trials Center, Silver Spring

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

GlaxoSmithKline

INDUSTRY

lead

U.S. Army Medical Research and Development Command

FED

NCT02421367 - Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults | Biotech Hunter | Biotech Hunter